ITCI Valuation

Intra-Cellular Therapies Inc

Add to Watchlist

Advanced Chart

0.000

-131.87(-100.000%)1D

Overview
Forecast
Valuation
Earnings

ITCI Relative Valuation

ITCI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ITCI is overvalued; if below, it's undervalued.

Historical Valuation

Intra-Cellular Therapies Inc (ITCI) is now in the Fair zone, suggesting that its current forward PS ratio of 14.76 is considered Fairly compared with the five-year average of -44.38. The fair price of Intra-Cellular Therapies Inc (ITCI) is between 104.86 to 211.99 according to relative valuation methord.

Relative Value

Fair Zone

104.86-211.99

Current Price：131.90

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

12.20

P/B

Median3y

8.85

Median5y

7.51

-0.52

FCF Yield

Median3y

-3.11

Median5y

-5.13

Competitors Valuation Multiple

The average P/S ratio for ITCI's competitors is 22.67, providing a benchmark for relative valuation. Intra-Cellular Therapies Inc Corp (ITCI) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 50.81%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ITCI.O

Intra-Cellular Therapies Inc

Loss

Average P/S: 22.67

50.81%